UPDATE: JPMorgan Upgrades Esperion Therapeutics (ESPR) to Neutral Citing 'Achievable Estimates as Outcomes Data Nears'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to UPDATE: JPMorgan Upgrades Esperion Therapeutics (ESPR) to Neutral Citing 'Achievable Estimates as Outcomes Data Nears'
May 3, 2022 3:19 PM EDT
Credit Suisse analyst Judah Frommer raised the price target on Esperion Therapeutics (NASDAQ: ESPR) to $7.00 (from $6.00) while maintaining a Neutral rating.... More
May 3, 2022 7:16 AM EDT
Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.93), $0.11 better than the analyst estimate of ($1.04). Revenue for the quarter came in at $18.8 million versus the consensus estimate of $15.39 million.
For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.
...
More
May 2, 2022 8:01 AM EDT
Esperion (NASDAQ: ESPR) today announced the publication of data from the CLEAR Harmony Open-Label Extension (OLE) Study of bempedoic acid, also known as NEXLETOL®, in the American Journal of Cardiology.
The paper, Long-term Safety and Efficacy of Bempedoic Acid in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (From the CLEAR Harmony Open-Label Extension Study), described the results from the 78-week, Phase 3, OLE study that followed the 52-week CLEAR Harmony Phase 3 study. In the CLEAR Harmony study, patients were randomized 2:1 to... More
